A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study
Loading...
Contact
Check for full-text access
Issue Date
Type
Journal article
Language
Keywords
Alternative Title
Abstract
Description
Citation
Publisher
License
Journal
Future Oncology
Volume
21
Issue
7